Intellia Therapeutics Inc (NTLA)
US$ 10.711%
Price Chart
Key Statistics
Market Cap
$ 990.25M
P/E Ratio
0.00
Revenue (TTM)
$ 45.57M
Volume
4.69M
52W High
$ 28.18
52W Low
$ 5.90
Dividend Yield
0.00%
Beta
2.13
Technicals
50-Day MA
8.4666
200-Day MA
12.1241
52 Week High
28.18
52 Week Low
5.9
About NTLA
Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments.
Employees
403
Headquarters
Cambridge, MA
CEO
Dr. John M. Leonard M.D.
Latest News
Top Gainers
Symbol/Name
LTP
% Chg
Top Losers
Symbol/Name
LTP
% Chg